National Research Corp (NASDAQ:NRCIB) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018. National Research Corp provides analytics and insights that improves measurement and improvement of the patient and employee experience. Its subscription-based solutions provide actionable information and analysis to healthcare organizations. National Research Corp has a market cap of $905.944 million; its shares were traded at around $53.01 with a P/E ratio of 58.90 and P/S ratio of 6.81. The dividend yield of National Research Corp stocks is 4.53%. National Research Corp had annual average EBITDA growth of 0.80% over the past ten years.
For the last quarter National Research Corp reported a revenue of $30.6 million, compared with the revenue of $29.90 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $119.7 million, an increase of 1.8% from last year. For the last five years National Research Corp had an average revenue growth rate of 5.5% a year. The National Research Corp enjoyed an operating margin of 29.47%, compared with the operating margin of 29.11% a year before. The 10-year historical median operating margin of National Research Corp is 26.07%. The profitability rank of the company is 5 (out of 10).
At the end of the fiscal year, National Research Corp has the cash and cash equivalents of $13.0 million, compared with $34.7 million in the previous year. The company had no long term debt. The interest coverage to the debt is at a comfortable level of 23.3. National Research Corp has a financial strength rank of 7 (out of 10).
At the current stock price of $53.01, National Research Corp is traded at 917.5% premium to its historical median P/S valuation band of $5.21. The P/S ratio of the stock is 6.81, while the historical median P/S ratio is 0.67. The stock gained 33.20% during the past 12 months.
For the complete 20-year historical financial data of NRCIB, click here.
No comments:
Post a Comment